Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging agent
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast cancer